Opdivo Showed 5-Year Survival Rates of 13.4% in 2nd-Line NSCLC in PIII Studies

Bristol-Myers Squibb has announced that the PD-1 inhibitor Opdivo (nivolumab) demonstrated 13.4% of five-year overall survival (OS) rates, according to the long-term pooled efficacy and safety results from two PIII studies, CheckMate-017 and CheckMate-057, in patients with second-line non-small cell...read more